Montano MD CV April
2013
C. Brendan Montano MD
Connecticut Clinical Research
160 West Street, Building 1, Suite A
Cromwell, Connecticut 06416
Phone (860) 632- 0144/Fax (860) 632-7882
e-mail DOCMONTANO@aol.com
cell: (860) 301-0760
Education:
1964-1968
1968-1972
1972-1975
College of the Holy Cross-Worcester, MA
BS Major Biology, Minor English
Albany Medical College-Albany, NY
St. Francis Hospital and Medical Center-Hartford, CT
Internal Medicine Residency
-Chief Resident-1975
-Yale University-Resident Rotations in Neurology and
Gastroenterology and Dermatology
Affiliations:
2000-Present Connecticut Clinical Research, Director of Metabolic and
Neuropsychiatric Research, Principle Investigator
1976-Present Attending Physician at Middlesex Memorial Hospital, Department of
Medicine, Middletown, CT
1978-Present Internal Medicine, Private Practice, Special interest in Preventive
Medicine and Mood Disorders, Cromwell, CT
2006-2009
Journal of Clinical Psychiatry for Primary Care: Editorial Board
2006-2010
CME Institute: Board of Directors
1972-2010
Courtesy Privileges St. Francis Hospital, Department of Medicine,
Hartford, CT
1991-2004
Director, New Beginnings Weight Management Center, Cromwell, CT
1983-1993
Medical Director at Roncalli Institute, Cromwell Crest Convalescent
Facility—Cromwell, CT
1985-1991
New England Heart Center—Medical Director-Manchester, CT
1
Montano MD CV April
2013
1978- 1985
Assistant Clinical Instructor, University of Connecticut School Of
Medicine, Department of Family Practice, Farmington, CT
Publications
Postgraduate Medicine, September 2012, 124(5), Discontinuity in the Transition From
Pediatric to Adult Health Care for Patients with AttentionDeficit/Hyperactivity Disorder, ISSN-0032-5481,eISSN-1941-9260
Postgraduate Medicine, May 2011, 123(3), 1-11. Distinguishing Symptoms of ADHD
From Other Psychiatric Disorder in the Adult Primary Care Setting.
Montano & Weisler. Issn- 0032-5481, eISSN – 1941-9260
Journal of Clinical Psychiatry, July 2011, 72(7), 1008-1015. Optimizing Clinical
Outcomes Across Domains of Life in Adolescents and Adults with
ADHD. Adler, Mattingly, Montano & Newcorn.
A Dynamic Patient Flow Model to Identify Areas to Improve Awareness and Diagnosis
in Adults With Attention Deficit Hyperactivity Disorder; Faraone, Willey,
Peterson, Stafford, Montano (pending)
Annals Clinical Psychiatry: Oct-Dec 2008 20(4):187-93 ISSN 1547-3325 “The Effect of
Pain on Outcomes in a Trial of Duloxetine Treatment of Major Depressive
Disorder. Arnold, Meyers, Sunderajan, Montano, Kass, Trivedi, Wohlriech
Medscape CME article: February 5, 2008 “Early to Late Adolescence: Issues and
Challenges in the Management of ADHA” Adesman, Greenberg, Pratt,
Goodman, Montano. Chapter 3 “Optimizing Physician-Patient
Communication in Adolescent ADHD
Archives of Internal Medicine, “Attention Deficit/Hyperactivity Disorder in Adults: A
Survey of Current Practice in Psychiatry and Primary Care”; Faraone,
Spencer, Montano, Beiderman: June 14, 2004; volume164, number 11
pages 1157-1252
Primary Psychiatry, February 2004: Vol 11, No 2, “Treatment of Depression:
Recognizing and Improving the Standard of Care” Norman Sussman, MD,
Pedro L. Delgado, MD, C. Brendan Montano, MD
Journal Of Clinical Psychiatry, The Diagnosis and treatment of Adult ADHD in Primary
Care: 2004 Feb., Vol 65, Supple: 3 18-21.
Journal of Family Practice. 2003 Dec; supple: S9-18 “Response to treatment: Gaining
and maintaining remission from depression.” Montano CB, Ashton AK,
2
Montano MD CV April
2013
D’Mello DA, Dantz B, Hefner J, Leon FG, Matson GA, Pradko JF,
Sussman N, Winsberg B.
PCC Visuals CME progam# 032-999-03-060-H01September 2003 “ Diagnosing and
Treating Attention-Deficit/Hyperactivity Disorder in Adults” Biederman,
Adler, Culpepper, Mason, Montano, Murphy, Roth, Spencer, Weiss,
Wilens.
Journal of Clinical Psychiatry 63:4 357-366, April 2002 “Prevalence of Sexual
Dysfunction among Newer Antidepressants” Clayton AH, Pradko JF,
Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KA,
Donahue RM, Jamerson BD, Metz A.
Medscape CME article 2002 C. Brendan Montano MD, Michael Montano “A New
Paradigm for Treating Depression in the Primary Care Setting”
Issues in Depression: Index & Reviews, Editor in Chief, Premier Issue November 1999
volume 1, Number 1, “Depression and Anxiety in the Elderly: Therapeutic
Challenges”
Journal of Clinical Psychiatry, Treatment of Depression in Long-Term Care Patients
1999 Volume 60, supplement 20 “Primary Care Issues Related to the
Treatment of Depression in Elderly Patients” Montano CB
Managed Care Interface, “The Effect of Panic Disorder in the Managed Care Setting” coauthored with Wayne Katon, M.D. and Richard Hart, M.D. May, 1997
Journal of Clinical Psychiatry, Supplement Managing Depression: New Perspectives
December 1994 Volume 55 No. 12 “Recognition and Treatment of
Depression in a Primary Care Setting” December, 1994-Vol. 55, No. 12,
Montano CB
Connecticut Medical Journal, “Stress Management Program with Biochemical Assay”
Sinatra, Montano, Hatch. July, 1982-Vol.46, No. 7
National Advisory Board and/or CME Consultant/Presenter:
Astra Zeneca, Bayer, GSK, Eli-Lilly, Forest, Ortho-McNiel, Organon,
Roche, Takeda, Wyeth, Shire
Research: Clinical Trial Experience
2013 Shire SPC489-329 A Phase 3, Open-label, Multicenter, 12-month Extension Safety
and Tolerability Study of SPD489 in Combination With an Antidepressant in the
3
Montano MD CV April
2013
Treatment of Adults with Major Depressive Disorder with Residual Symptoms or
Inadequate Response to Prospective Treatment with an Antidepressant.
2012 Shire SPC489-209 A Phase 2, Multicenter, Double-blind Parallel-group,
Randomized Placebo-controlled, Forced dosed titration, Dose-ranging Efficacy
and Safety study of SPC480 in Combination with an Antidepressant in the
Treatment of Adults with Major Depressive Disorder with Inadequate Response
Following Treatment with an Antidpressant
2012 Bristol-Myers Squibb, CN160010 A Multicenter, Double- Blind, 58 week
Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients
with Treatment Resistant Major Depression.
2012 Bristol-Myers Squibb, CN162007A Multicenter, Randomized, Double-blind,
Active-Controlled, Comparative, Fixed-Dose, Dose Response Study of the
Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major
Depression
2012
Forest Research Institute, VLZ-MD-01 A Double –Blind, Placebo- and ActiveControlled, Fixed-Dose Study of Vilazodone in Patiens with Major Depressive
Disorder
2012
Forest Research Institute, VLZ-MD-02 A Double-Blind, Placebo- and ActiveControlled Fixed-Dose Study of Vilazolone in Patients with Major Depressive
Disorder
2012
Forest NAC-MD-02 A Multicenter, Open-Label, Single-Arm, Free Tablet
Combination, Long-Term Study to Evaluate the Safety of Nevivolol in
Combination with Valsartan in Patients with State 1 or Stage 2 Essential
Hypertension
2011
Forest NAC-MD-01 A Mulitcenter, Randomized, Double-blin, PlaceboControlled, 8 –Week Study to Evaluate the Safety and Efficacy of Nebivolol and
valsartan Given as a Fixed-Dose Combination in Patients with State 1 or 2
Essential Hypertension
2010 Otsuka 31-08-255 A Multicenter, Randomized, Double-blind Study to
Evaluate the Efficacy, Safety and Tolerability of an Oral
Aripiprazole/Escitalopram Combination Therapy in Patients With Major
Depressive Disorder
2010 Shire SPD489-205 A Phase 2, Multicenter, Randomized, Double-blind,
Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and
Tolerability of SPD489 in Adults with Clinically Significant, Persistent
4
Montano MD CV April
2013
Executive Function Impairments (EFE) and Partial or Full Remission of
Recurrent Major Depressive Disorder
2010
Forest LVM MD 04 A Long-Term, Open-label Extension Study of F2695
SR in Adult Patients With Major Depressive Disorder
2010 Forest LVM MD 01 A Double Blind Placebo Controlled Fixed-Dose Study of
F2695 SR in Patients With Major Depressive Disorder
2010 Pfizer/Wyeth 3151 A1 4437 A Randomized, Double-Blind, Parallel Group
Study to Compare Discontinuation Symptoms in Abrupt Discontinuation
Versus a 1-week Tapering Regimen in Subjects with Major Depressive
Disorder (MDD) Treated for 24 Weeks with Open-Label 50 mg
Desvenlafazine Succinate Sustained-Release Formulation (DVS SR)
2010
Pfizer/Wyeth 3151 A1 3364 A Multicenter, Parallel-Group, Randomized, 10
Week, Double-Blind, Placebo-Controlled Parallel Group
Study to Compare Discontinuation Symptoms in Abrupt Discontinuation
Versus a 1-week Tapering Regimen in Subjects with Major Depressive
Disorder (MDD) Treated for 24 Weeks with Open-Label 50 mg
Desvenlafazine Succinate Sustained-Release Formulation (DVS SR)
2010 Eli Lilly F1J MC HMGU Duloxetine Versus Placebo in the Acute Treatment
of Patients with Major Depressive Disorder and Associated Painful Physical
Symptoms
2009- 2010 Eli Lilly H6P-MC-HDAY A Study to Assess the Long-Term Efficacy and
Safety of Olanzapone and Fluoxetine Combination Versus Fluoxetine
Treatment-Resistant Depression Signatures
2009-2010 Eli Lilly F1J-US-HMGL A Randomized, Placebo-Controlled Trial of
Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients with
Knee Pain due to Osteoarthritis who have had Suboptimal Response to
Nonsteroidal Anti-inflammatory Drug Treatment
2009 – 2010Wyeth 3151A1 -3362 A Multicenter Randomized, Double-Blind PlaceboControlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2
Fixed Doses (10 and 50mg/day) of DVS SR Tablets in Adult Outpatients
with Major Depressive Disorder.
2009-2010 Forest MLN MD 28 A Multicenter, Randomized , Double-Blind,
5
Montano MD CV April
2013
Placebo-Controlled switch study To Evaluate The Safety, Tolerability and
Efficacy Of Milnacipran In Patients With An Inadequate Response To
Duloxetine For the Treatment of Fibromyalgia
2009
Forest MLN MD 27 A Multicenter, Randomized, Open-Label, Controlled
Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran
When Added to Pregabalin in the Treatment of Fibromyalgia
2008
Takeda A Randomized, double-Blind, Parallel-Group, Placebo-Controlled,
Fixed –Dose Study Comparing the Efficacy and Safety of 2 Doses of
Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety
Disorder.
2008
Novartis Protocol CSPP100A US07 An 8-week Prospective, Multicenter,
Randomized, Double-Blind, Active Control, Parallel Group Study to
Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese
patients (BMI > = 30 ) with Stage 2 Hypertension.
2008- 2009 Eli Lilly Protocol F1J-MC-HMGC Effects of Duloxetine 60mg Once Daily
Versus Placebo in Patients with Chronic Low back Pain
2008- 2009 Eli Lilly Protocol F1J-MC-HMGB Flexible Dosed Duloxetine Versus \
Placebo in the Treatment of Fibromyalgia
2008- 2009 Eli Lilly Protocol F1J-MC-HMEZ An open-Label, Randomized
Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine
and Gabapentin Among Patients with Inadequate Response to Gabapentin
for the Management of Diabetic Peripheral Neuropathic Pain.
2007-2008 Schwarz Biosciences Protocol SP888 A Parallel, Randomized, Doubleblind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the
Efficacy and Safety of two Different Transdermal Doses of Rotigotine in
Subjects with Signs and Symptoms Associated with Fibromyalgia
Syndrome.
2007-2009
Forest/Cypress Protocol MLN-MD-06 A Phase III, Multicenter. OpenLabel, Flexible-Dosing Study of Milnacipran For The Treatment Of
Fibromyalgia.
2007-2008
Forest/Cypress Protocol MLN-MD-03
“A Phase III Pivotol, Multicenter, Double-Blind, Randomized, PlaceboControlled Monotherapy Study Of Milnacipran For the Treatment of
Fibromyalgia.”
6
Montano MD CV April
2013
2007
Eli Lilly F1J-MC-HMEO
Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain
2007
Wyeth 3151A1-402WW
A Multicenter, Randomized, 8 Week Double Blind Acute Phase Followed
by a 6 Month Continuation Phase (Open Label or Double blind) study to
Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus
Escitalopram in Postmenopausal Women with Major Depressive Disorder.
2007
Novartis CAGO178A2301E1
An 8 Week, Randomized, Double-Blind, Fixed-Dosage, PlaceboControlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and
Tolerability of Agomelatine 25 and 50 mg in the Treatment of Major
Depressive Disorder (MDD) Followed by a 52 Week Open Label
Extension.
2007
Sanofi Aventis EFC 5582
An Eight-week, Multcenter, Randomized, Double-blind, Placebo-controlled
Study, Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses
(100mg and 30 Mg Once Daily) of Saredutant in Patients with Generalized
Anxiety Disorder.
2006-2007
Takeda Protocol# 01-05-TL-322OPI-001 “A Multicenter, Randomized,
Double-Blind, Placebo-Controlled Study to Determine the Efficacy and
Safety of the Combination of SYR-322 and Pioglitazone HCI in Subjects
with Type 2 Diabetes.”
2006-2007
Eli Lilly Protocol # F3Z-US-IOOV(a) “ The Durability of Twice-Daily
Insulin Lispro Low Mixture Compared to Once-daily Insulin Glargine
when added to Existing Oral Therapy in Patients with Type 2 Diabetes and
Inadequate Glycemic Control.”
2006-2007
Sanofi Aventis Protocol EFC5116 “An eight –week, double-blind, placebo
controlled, multicenter study with Escitalopram as a positive control,
evaluating the efficacy,, safety, tolerability of a fixed dose of SR58611A in
outpatients with MDD”
2006-2007
Wyeth Protocol 3151A4-327-330 A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy and
Tolerability Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients
2006-2007
Wyeth Protocol 00600B1-416-US
7
Montano MD CV April
2013
Patient Outcomes with Educaiton, Drug Therapy and Support(POETS)
A Multiconeter, Open-Label, Randomized Study to Evalute Depressed
Subjects treated with Venlafaxine Extended Release vs Venlafaxine
Extended Release Plus the Dialogues to Talk Program in a Primary Care
Setting
2006
AstraZeneca Protocol D1448C00005 “ A Multi-Centre, Double-Blind,
Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase III
Study of the Efficacy and Safety of Quetiapine Fumarate Sustained
Release (Seroquel SR) as Monotherapy in the Maintenance treatment of
Patients with Major Depressive Disorder Following an Open-Label
Stabilization Period (Amethyst Study)
2006
Aventis Protocol HMR3647A/4019 “ A Randomized, Double-Blind,
Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes
of Telithromycin verses Azithromycin in Outpatients with CommunityAquired Lower Respiratory Tract Infections”
2005-2006
Predix Pharmaceuticals Protocol PRX-CP-007 “A Randomized, Double
Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy,
Safety, and Tolerability Of PRX-0023 In Patients With Generalized
Anxiety Disorder (GAD)
2005-2007
Eli-Lilly Protocol F1J-MC-HMEF(a) “Duloxetine 60/120 mg Versus
Placebo in the Treatment of Fibromyalgia Syndrome”
2004-2005
F. Hoffmann-La Roche LTD Protocol ML 18056 “Prospective, Openlabel, Multi-center, Two-part Study To Investigate Patient Satisfaction
With Monthly Dosed Ibandronate Therapy In Women With
Postmenopausal Osteoporosis Or Osteopenia Transitioned from OnceWeekly Alendronate Or Risedronate2
2004-2005
F. Hoffmann-La Roche LTD Protocol MA17843 “Randomized, Open-Label,
Multi-Center Study to Investigate Patient Preference on Dosing in Women with
Postmenopausal Osteoporosis Treated with Once-Monthly Ibnadroate and OnceWeekly Alendronate. A Six-Month, Two-Period Crossover Study”
2003-2004
GSK Protocol AK103091: A Multicenter, Double-Blind Placebo Controlled
Comparison of the Efficacy and Safety of Flexible Dose Extended-Release
Bupropion Hydrochloride (HCI) 300-450 mg/day and Placebo Administrated for
Eight Weeks for the Treatment of Adult Outpatients with Major Depressive
Disorder Including Symptoms of Decreased Energy, Pleasure and Interest.
2003- 2005
8
Eli-Lilly Protocol F1J-MC-HMBV: Duloxetine Versus Placebo in the Treatment of
Montano MD CV April
2013
2003- 2004
Eli-Lilly Protocol H6K-MC-LVFN: An Open-Label Study to Evaluate the
Efficacy and Safety of Tadalafil Administered “On Demand” to Men of
Various Populations with Erectile Dysfunction.
2002- 2005
Eli-Lilly Protocol F1J-US-HMBZ: Open –Label Treatment with
Duloxetine Hydrochloride once-Daily dosing for Evaluation of
Stabilization Dose in Patients with Major Depression.
2001- 2003
Takeda Protocol 01-00-TL-OPI-506: A Randomized Comparator,
Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCI
Versus Glyburide with Metformin and Insulin as Part of Step Therapy in
Subjects with Type 2 Diabetes.
2001-2002
Aventis Pharmaceuticals Inc.: Ketek Protocol
HMR3647A/3014Telithromycin Randomized, Open-Label, Multicenter
Trial of the Safety and Effectiveness of Oral Telithromycin and
Amoxicillin/Clavulanic Acid in Outpatients with Respiratory Tract
Infections in Usual Care Settings
2000-2001
GSK Protocol AK140020 Study Chairperson, Protocol Sexual Dysfunction
with Antidepressant Medication in the Primary Care Setting
2000
Bristol-Meyers Squibb Protocol A1420088 Bronchitis and Pneumonia
1998-2000
Hoffman-Roche Protocol M37048/NR158 Krista Treatment Plus Diet in
Obese Type 2 Diabetes Patients on Metformin
1998-1999
Hoffman –Roche Protocol M37049/NR158 Orlistat Plus Diet in Obese
Hypertensive Patients
1996-2000
1996-2001
1997-1998
1994-1995
1994-1995
1994-1996
Searle Protocol 1296011 Convince: Hypertension
Forrest Protocol CITMD49815 Early Experience: Depression
Target: Hyperlipidemia—Park-Davis Phase V
Pratt Protocol P-0001 GEST: Diabetes
Pfizer Protocol R-0235 Sertraline: Depression, open label, multicenter
SKB Protocol PAR/23 Paroxatine: Depression Phase III
9